Comparison between Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Levels in Rhegmatogenous Retinal Detachment.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
05
2021
accepted:
22
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
12
2021
Statut:
epublish
Résumé
This study aimed to assess vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) levels within vitreous and blood serum samples of patients with rhegmatogenous retinal detachment (RRD) and their relationship to the development of proliferative vitreoretinopathy (PVR). Seventeen eyes of patients with RRD were included in the RRD group and divided into three subgroups: RRD without PVR, RRD with PVR grades A and B, and RRD with PVR grade C. Five control eyes (nucleus and intraocular lens drop) were included in this study. Blood serum and vitreous samples were collected during vitrectomy. VEGF-A and PDGF-AA levels were determined by enzyme-linked immunosorbent assay. The mean vitreous VEGF-A level in the RRD group was 131.71 ± 58.25 pg/mL, and the mean vitreous PDGF-AA level was 174.62 ± 65.17 pg/mL. Both levels were significantly higher in the RRD group compared with the control group ( Based on the tendency of VEGF-A and PDGF-AA levels, RRD surgery has to be performed as soon as possible prior to retinal cell death and membrane proliferative formation.
Identifiants
pubmed: 34912575
doi: 10.1155/2021/2688837
pmc: PMC8668303
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2688837Informations de copyright
Copyright © 2021 Andi Muhammad Ichsan et al.
Déclaration de conflit d'intérêts
The authors state that there are no conflicts of interest regarding this article.
Références
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2683-9
pubmed: 10509666
Invest Ophthalmol Vis Sci. 2012 Oct 23;53(11):7316-21
pubmed: 23033395
Rom J Ophthalmol. 2015 Apr-Jun;59(2):88-92
pubmed: 26978867
Mol Cell Biol. 2011 May;31(9):1788-99
pubmed: 21357737
PLoS One. 2011 Apr 27;6(4):e19141
pubmed: 21556354
Mol Vis. 2014 Sep 21;20:1357-65
pubmed: 25352742
J Cell Sci. 1994 Sep;107 ( Pt 9):2459-69
pubmed: 7844163
Prog Retin Eye Res. 2006 Mar;25(2):149-64
pubmed: 16377232
Mediators Inflamm. 2012;2012:815937
pubmed: 23049173
Exp Eye Res. 2010 Mar;90(3):376-81
pubmed: 19931527
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):2001-6
pubmed: 12037011
Br J Ophthalmol. 2001 Apr;85(4):461-70
pubmed: 11264138
J Ophthalmol. 2016;2016:7807596
pubmed: 27429798
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3394-403
pubmed: 19324843
Br J Ophthalmol. 1997 Oct;81(10):919-26
pubmed: 9486038
J Ocul Pharmacol Ther. 2000 Oct;16(5):463-9
pubmed: 11110038
J Fr Ophtalmol. 2014 Sep;37(7):557-65
pubmed: 24997864
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8146-53
pubmed: 23139279
Mol Cell Biol. 2012 May;32(10):1955-66
pubmed: 22431518
Retina. 2012 Jan;32(1):54-9
pubmed: 21836532
Prog Retin Eye Res. 2015 Nov;49:67-81
pubmed: 26113211
Exp Eye Res. 2009 Mar;88(3):438-44
pubmed: 19032953
Curr Eye Res. 2010 Jun;35(6):505-9
pubmed: 20465445
Br J Ophthalmol. 2011 Sep;95(9):1234-8
pubmed: 21156702